# Bone Loss in Melanoma Survivors Receiving Immunotherapy

> **NCT04516122** · — · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Pathologic Stage III Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Pathologic Stage IV Cutaneous Melanoma AJCC v8

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Dual X-ray Absorptiometry

## Key facts

- **NCT ID:** NCT04516122
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-10
- **Primary completion:** 2025-06-18
- **Final completion:** 2025-06-18
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** \<75% participation
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04516122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04516122, "Bone Loss in Melanoma Survivors Receiving Immunotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04516122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*